PGAM1 suppression remodels the tumor microenvironment in triple-negative breast cancer and synergizes with anti–PD-1 immunotherapy
Journal of Leukocyte Biology · 2024
DOI: 10.1093/jleuko/qiae065 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Leukocyte Biology, 2024. Verfasst von Dong Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Huanhuxi Road, Hexi District, Tianjin, 300060…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Tumor Microenvironment, Immunotherapy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Haihe Laboratory of Cell Ecosystem Innovation.
Abstract (Originalsprache)
Triple-negative breast cancer is a high-risk form of breast cancer with a high metastatic potential and lack of effective therapies. Immunotherapy has shown encouraging clinical benefits, and its efficacy in triple-negative breast cancer is affected by immunocyte infiltration in the tumor microenvironment. PGAM1 is a key enzyme involved in cancer metabolism; however, its role in the tumor microenvironment remains unclear. In this study, we aimed to investigate the role of PGAM1 in triple-negative breast cancer and determine the potential of PGAM1 inhibition in combination with anti–PD-1 immunotherapy. Our results showed that PGAM1 is highly expressed in triple-negative breast cancer and is associated with poor prognosis. In vivo experiments demonstrated that PGAM1 inhibition synergizes with anti–PD-1 immunotherapy, significantly remodeling the tumor microenvironment and leading to an increase in antitumor immunocytes, such as CD8+ T cells and M1 macrophages, and a reduction in immunosuppressive cell infiltration, including myeloid-derived suppressor cells, M2 macrophages, and regulatory T cells. Functional and animal experiments showed that this synergistic mechanism inhibited tumor growth in vitro and in vivo. We identified PGAM1 as a novel target that exhibits an antitumor effect via the regulation of immunocyte infiltration. Our results show that PGAM1 can synergize with anti–PD-1 immunotherapy, providing a novel treatment strategy for triple-negative breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Huanhuxi Road, Hexi District, Tianjin, 300060, China.
- Key Laboratory of Cancer Prevention and Therapy, Huanhuxi Road, Hexi District, Tianjin, 300060, China.
- Tianjin's Clinical Research Center for Cancer, Huanhuxi Road, Hexi District, Tianjin, 300060, China.
- Key Laboratory of Cancer Immunology and Biotherapy, Huanhuxi Road, Hexi District, Tianjin, 300060, China.
- Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Huanhuxi Road, Hexi District, Tianjin, 300060, China.
- Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Road, Hexi District, Tianjin, 300060, China.
Förderung
- National Natural Science Foundation of China
- Haihe Laboratory of Cell Ecosystem Innovation
Zitieren
APA
Zhang, D., Wang, M., Wang, W., Ma, S., Yu, W., Ren, X., & Sun, Q. (2024). PGAM1 suppression remodels the tumor microenvironment in triple-negative breast cancer and synergizes with anti–PD-1 immunotherapy. Journal of Leukocyte Biology. https://doi.org/10.1093/jleuko/qiae065
Vancouver
Zhang D, Wang M, Wang W, Ma S, Yu W, Ren X, et al. PGAM1 suppression remodels the tumor microenvironment in triple-negative breast cancer and synergizes with anti–PD-1 immunotherapy. Journal of Leukocyte Biology. 2024. doi:10.1093/jleuko/qiae065
BibTeX
@article{Zhang2024,
author = {Zhang, Dong and Wang, Min and Wang, Wenying and Ma, Shiya and Yu, Wenwen and Ren, Xiubao and Sun, Qian},
title = {PGAM1 suppression remodels the tumor microenvironment in triple-negative breast cancer and synergizes with anti–PD-1 immunotherapy},
journal = {Journal of Leukocyte Biology},
year = {2024},
doi = {10.1093/jleuko/qiae065}
}
EUVIMED